Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-based H5N1 Influenza Vaccine

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Mar 21

PMID 22432020

Citations 49

Authors

Aseem Pandey

Neetu Singh

Sai V Vemula

Laurent Couetil

Jacqueline M Katz

Ruben Donis

Suryaprakash Sambhara

Suresh K Mittal

Affiliations

Soon will be listed here.

Abstract

The prevalence of preexisting immunity to adenoviruses in the majority of the human population might adversely impact the development of adaptive immune responses against adenovirus vector-based vaccines. To address this issue, we primed BALB/c mice either intranasally (i.n.) or intramuscularly (i.m.) with varying doses of wild type (WT) human adenovirus subtype 5 (HAd5). Following the development of immunity against HAd5, we immunized animals via the i.n. or i.m. route of inoculation with a HAd vector (HAd-HA-NP) expressing the hemagglutinin (HA) and nucleoprotein (NP) of A/Vietnam/1203/04 (H5N1) influenza virus. The immunogenicity and protection results suggest that low levels of vector immunity (<520 virus-neutralization titer) induced by priming mice with up to 10(7) plaque forming units (p.f.u.) of HAd-WT did not adversely impact the protective efficacy of the vaccine. Furthermore, high levels of vector immunity (approximately 1500 virus-neutralization titer) induced by priming mice with 10(8) p.f.u. of HAd-WT were overcome by either increasing the vaccine dose or using alternate routes of vaccination. A further increase in the priming dose to 10(9) p.f.u. allowed only partial protection. These results suggest possible strategies to overcome the variable levels of human immunity against adenoviruses, leading to better utilization of HAd vector-based vaccines.

Citing Articles

The frequency and function of nucleoprotein-specific CD8 T cells are critical for heterosubtypic immunity against influenza virus infection.

Amoah S, Cao W, Sayedahmed E, Wang Y, Kumar A, Mishina M J Virol. 2024; 98(8):e0071124.

PMID: 39082839 PMC: 11334528. DOI: 10.1128/jvi.00711-24.

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines.

Moral-Sanchez I, Wee E, Xian Y, Lee W, Allen J, Torrents de la Pena A NPJ Vaccines. 2024; 9(1):74.

PMID: 38582771 PMC: 10998906. DOI: 10.1038/s41541-024-00862-8.

Enhancement of mucosal innate and adaptive immunity following intranasal immunization of mice with a bovine adenoviral vector.

Sayedahmed E, Elshafie N, Zhang G, Mohammed S, Sambhara S, Mittal S Front Immunol. 2023; 14:1305937.

PMID: 38077380 PMC: 10702558. DOI: 10.3389/fimmu.2023.1305937.

Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine.

Sayedahmed E, Araujo M, Silva-Pereira T, Chothe S, Elkashif A, Alhashimi M Mol Ther Methods Clin Dev. 2023; 30:194-207.

PMID: 37502665 PMC: 10299838. DOI: 10.1016/j.omtm.2023.06.009.

An Old Acquaintance: Could Adenoviruses Be Our Next Pandemic Threat?.

Saint-Pierre Contreras G, Conei Valencia D, Lizama L, Vargas Zuniga D, Avendano Carvajal L, Ampuero Llanos S Viruses. 2023; 15(2).

PMID: 36851544 PMC: 9966032. DOI: 10.3390/v15020330.

References

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Vos A, Neubert A, Pommerening E, Muller T, Dohner L, Neubert L . Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. J Gen Virol. 2001; 82(Pt 9):2191-2197. DOI: 10.1099/0022-1317-82-9-2191. View

Lemiale F, Kong W, Akyurek L, Ling X, Huang Y, Chakrabarti B . Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol. 2003; 77(18):10078-87. PMC: 224584. DOI: 10.1128/jvi.77.18.10078-10087.2003. View

Mast T, Kierstead L, Gupta S, Nikas A, Kallas E, Novitsky V . International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2009; 28(4):950-7. DOI: 10.1016/j.vaccine.2009.10.145. View

Neutra M, Kozlowski P . Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006; 6(2):148-58. DOI: 10.1038/nri1777. View

Hoelscher M, Jayashankar L, Garg S, Veguilla V, Lu X, Singh N . New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther. 2007; 82(6):665-71. PMC: 2793094. DOI: 10.1038/sj.clpt.6100418. View

Barouch D, Nabel G . Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther. 2005; 16(2):149-56. DOI: 10.1089/hum.2005.16.149. View

Singh N, Pandey A, Jayashankar L, Mittal S . Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther. 2008; 16(5):965-71. PMC: 2700267. DOI: 10.1038/mt.2008.12. View

Zhu J, Huang X, Yang Y . Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J Virol. 2007; 81(7):3170-80. PMC: 1866082. DOI: 10.1128/JVI.02192-06. View

10.

Stephenson I, Wood J, Nicholson K, Charlett A, Zambon M . Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004; 103(1-2):91-5. DOI: 10.1016/j.virusres.2004.02.019. View

11.

Lubeck M, Davis A, Chengalvala M, Natuk R, MORIN J, Mason B . Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A. 1989; 86(17):6763-7. PMC: 297926. DOI: 10.1073/pnas.86.17.6763. View

12.

Bender B, Small Jr P . Influenza: pathogenesis and host defense. Semin Respir Infect. 1992; 7(1):38-45. View

13.

Van Kampen K, Shi Z, Gao P, Zhang J, Foster K, Chen D . Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2004; 23(8):1029-36. DOI: 10.1016/j.vaccine.2004.07.043. View

14.

Thomas P, Keating R, Hulse-Post D, Doherty P . Cell-mediated protection in influenza infection. Emerg Infect Dis. 2006; 12(1):48-54. PMC: 3291410. DOI: 10.3201/eid1201.051237. View

15.

Yang Y, Jooss K, Su Q, Ertl H, Wilson J . Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 1996; 3(2):137-44. View

16.

Kostense S, Koudstaal W, Sprangers M, Weverling G, Penders G, Helmus N . Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS. 2004; 18(8):1213-6. DOI: 10.1097/00002030-200405210-00019. View

17.

van Olphen A, Mittal S . Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted. J Virol. 2002; 76(12):5882-92. PMC: 136187. DOI: 10.1128/jvi.76.12.5882-5892.2002. View

18.

Mittal S, McDermott M, Johnson D, Prevec L, Graham F . Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter. Virus Res. 1993; 28(1):67-90. DOI: 10.1016/0168-1702(93)90090-a. View

19.

Gao W, Soloff A, Lu X, Montecalvo A, Nguyen D, Matsuoka Y . Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol. 2006; 80(4):1959-64. PMC: 1367171. DOI: 10.1128/JVI.80.4.1959-1964.2006. View

20.

van Olphen A, Tikoo S, Mittal S . Characterization of bovine adenovirus type 3 E1 proteins and isolation of E1-expressing cell lines. Virology. 2002; 295(1):108-18. DOI: 10.1006/viro.2002.1389. View